Leo Pharma pays up to $435M for rights to Tanabe's oral therapy for sun-triggered skin conditions
Leo Pharma has agreed to pay Japan's Tanabe Pharma as much as $435 million in upfront and near-term fees to license an oral medication targeting two inherited skin disorders that cause pain upon sun exposure. The Danish company will take over development and commercialization of the drug, which addresses a rare patient population with significant unmet need. Financial terms include milestone-based payments beyond the initial sum, though specific amounts were not disclosed.
The agreement transfers global development and marketing duties for the oral candidate to Leo Pharma, a Danish firm. Tanabe Pharma, based in Japan, will receive an initial package of $435 million, which includes upfront and near-term payments, plus undisclosed milestone fees tied to future progress.
The therapy targets two rare inherited conditions where sunlight exposure triggers significant pain. Because current options are limited for this specific patient group, the deal highlights a focus on addressing a high unmet medical need within a small population.
If successful, this oral therapy could offer a more convenient alternative to existing preventive measures for patients with these rare sun-triggered disorders, potentially improving daily quality of life. The substantial upfront investment may also signal growing commercial interest in niche dermatological conditions, encouraging further research into similar rare diseases where treatment gaps persist.